Navigation Links
BGI to play a pivotal role in demonstrating the superior performance of RNA-Seq
Date:11/2/2011

November 2nd, 2011, Shenzhen, China - BGI, the world's largest genomic organization, today announced its participation and pivotal role in demonstrating the superior performance of RNA-Seq in predicting patient outcomes as part of the Sequencing Quality Control (SEQC) Project launched by the U.S. Food and Drug Administration (FDA). The SEQC, also known as MAQC-III, is the third phase of the MicroArray Quality Control (MAQC), aimed at assessing the technical performance of next-generation sequencing (NGS) platforms for RNA and DNA analyses.

Microarrays were expected to be a primary source for pharmacogenomic and toxicogenomic data, but its progress has been hampered due to concerns on the lack of reproducibility and accuracy of the derived data. Recently, more and more scientists have been gradually conducting pharmaceutical and medical studies by utilizing NGS technology for advancing personalized nutrition and medicine. In late 2008, FDA turned its attention to sequencing technology and issued a statement calling for volunteers to participate in SEQC.

With the rapid development of NGS technology, RNA-Seq, also known as "Whole Transcriptome Shotgun Sequencing," is being adopted by the biomedical research community and FDA-regulated industries because of its potential for higher sensitivity in detecting low expression genes and greater specificity in distinguishing isoforms, among other advantages. To demonstrate the utility of RNA-Seq technology in predicting patient outcomes, the FDA, BGI and the University Children's Hospital of Cologne have been conducting together a study of cancer prognosis to assess the performance of RNA-Seq and microarrays using 500 neuroblastoma samples from MAQC-II.

In this project, BGI performs sequence library construction and sequencing as well as bioinformatics analysis for the massive amount of data being produced. "With our rich experience in RNA-Seq research, we believe we can make a significant contribution to the development of RNA-Seq technology and help accelerate its translation to clinical application," said Dr. Zhiyu Peng, Vice President of Research & Cooperation Division at BGI.

Dr. Matthias Fischer from the University Children's Hospital of Cologne stated, "While we have built predictive models for neuroblastoma patients with microarray data, some of those still need to be improved. Compared with microarray, the resulting massive RNA-Seq sequence data could be utilized to better understand human transcriptomics and identify functional genetic variants associated with disease and drug risks."


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Related biology news :

1. CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011
2. BGI to Play Pivotal Sampling, Next-Generation Sequencing and Bioinformatics Role in Earth Microbiome Project
3. Pivotal discoveries in age-related macular degeneration
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. Volcanoes played pivotal role in ancient ice age, mass extinction
6. SRNL demonstrating low-energy remediation with patented microbes
7. Seeking superior stem cells
8. Fat and healthy? York U study finds slim isnt always superior
9. AgriLife research: Multi-paddock grazing is superior to continuous grazing
10. Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management
11. First new C. difficile drug in a generation superior to existing treatments: Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):
(Date:5/26/2017)... ... May 25, 2017 , ... Throughout this webinar, participants will ... process development and economic goals were achieved in both industry and academic settings. ... system, along with techniques for scaling production of mesenchymal stem cells (MSCs) and ...
(Date:5/24/2017)... BOUNTIFUL, Utah (PRWEB) , ... May 24, 2017 ... ... announces the selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery ... a key component of a $24 million plant upgrade to sustainably meet current ...
(Date:5/24/2017)... May 23, 2017 As Ebola resurfaces in the ... deaths and 20 suspected cases now reported, a new analysis ... database, showed a correlation between the 2014 and 2017 outbreaks ... rose sharply in 2012-13, which preceded the 2014 outbreak. An ... Ebola gene Replikin counts in 2014-15, which again precedes the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
Breaking Biology Technology: